Global Chronic Kidney Disease CKD Drugs Market Size By Type (ACE Inhibitors, Angiotensin-II Receptor Blockers), By Application (Hospitals, Specialty Clinics), By Region, And Segment Forecasts, 2023 to...

The Global Chronic Kidney Disease (CKD) Drugs Market was valued at USD 15.3 billion in 2023 and is projected to reach USD 26.8 billion by 2031, growing at a CAGR of 7.3% during the forecast period from 2023 to 2031. This growth is driven by the rising prevalence of chronic kidney disease worldwide, growing awareness of early diagnosis, and advancements in pharmacological treatments including renin-angiotensin system inhibitors, erythropoiesis-stimulating agents (ESAs), and phosphate binders. The increasing elderly population and growing incidence of comorbid conditions such as diabetes and hypertension further support the demand for CKD drugs.

Drivers:

Rising Global Prevalence of CKD:

With over 850 million individuals affected by kidney disease globally, the need for effective treatment solutions is surging. The progression of CKD into end-stage renal disease (ESRD) necessitates long-term pharmacological management, driving the demand for CKD drugs.

Aging Population and Associated Comorbidities:

The elderly population is more susceptible to CKD due to age-related decline in renal function and higher incidence of hypertension and diabetes, boosting the need for targeted drug therapies.

Advancements in Drug Development:

Ongoing clinical trials and regulatory approvals of new drugs, including SGLT2 inhibitors for CKD patients with and without diabetes, are expanding the treatment landscape.

Restraints:

High Treatment Costs:

The cost burden associated with long-term treatment of CKD, especially with newer biologics and patented drugs, poses a challenge, particularly in low- and middle-income regions.

Adverse Drug Effects and Regulatory Hurdles:

Several CKD drugs, such as ESAs, are linked to cardiovascular side effects, leading to cautious use. Additionally, stringent regulatory requirements can delay market entry for new therapies.

Opportunity:

Emerging Therapeutics and Biomarker-based Approaches:

Biomarker-based CKD stratification and personalized treatment are transforming the drug development pipeline, offering significant market potential.

Growth in Emerging Markets:

Rising healthcare investments and awareness campaigns in Asia-Pacific and Latin America present lucrative growth opportunities, as early-stage diagnosis and treatment uptake increase.

Market by System Type Insights:

The Renin-Angiotensin System Inhibitors segment held the largest share in 2023 due to their pivotal role in slowing CKD progression and reducing proteinuria. The SGLT2 inhibitors segment is expected to witness the fastest growth rate during the forecast period, fueled by clinical evidence supporting their renoprotective benefits even in non-diabetic CKD patients.

Market by End-use Insights:

In 2023, the Hospital Pharmacies segment dominated the market, driven by the high volume of CKD treatments administered in clinical settings. However, Online Pharmacies are projected to grow rapidly, benefiting from the global shift toward digital health services and increasing access to prescription drugs online.

Market by Regional Insights:

North America led the global CKD drugs market in 2023, supported by a robust healthcare infrastructure, higher CKD awareness, and advanced diagnostic capabilities. Asia-Pacific is expected to experience the highest CAGR, driven by the growing burden of diabetes, improving healthcare access, and government-led CKD screening initiatives in countries like China and India.

Competitive Scenario:

Key players in the global chronic kidney disease drugs market include AbbVie Inc., AstraZeneca, Johnson & Johnson, Bayer AG, Pfizer Inc., Amgen Inc., Boehringer Ingelheim, GlaxoSmithKline plc, Sanofi, and Novartis AG. These companies are focusing on R&D investments, strategic collaborations, and the expansion of therapeutic indications for existing drugs.

Key Developments:

In 2023, AstraZeneca received extended FDA approval for dapagliflozin to treat CKD in patients irrespective of diabetes status.

Bayer AG launched Kerendia (finerenone) in new markets in 2024 after receiving EMA approval for CKD patients with type 2 diabetes.

Amgen Inc. expanded its ESA product line with biosimilar developments to increase global market accessibility.

Scope of Work – Global Chronic Kidney Disease (CKD) Drugs Market

Report Metric Details

Market Size (2023) USD 15.3 Billion

Projected Market Size (2031) USD 26.8 Billion

CAGR (2023–2031) 7.3%

Market Segments By Drug Class, By End-use, By Region

Growth Drivers Rising CKD prevalence, aging population, SGLT2 uptake

Opportunities Personalized medicine, emerging markets

FAQs:

1) What is the current market size of the Global Chronic Kidney Disease (CKD) Drugs Market?

The market was valued at USD 15.3 billion in 2023.

2) What is the major growth driver of the Global Chronic Kidney Disease (CKD) Drugs Market?

The primary growth driver is the rising global prevalence of CKD coupled with increasing therapeutic innovation.

3) Which is the largest region during the forecast period in the Global Chronic Kidney Disease (CKD) Drugs Market?

North America accounted for the largest regional market share in 2023.

4) Which segment accounted for the largest market share in Global Chronic Kidney Disease (CKD) Drugs Market?

The Renin-Angiotensin System Inhibitors segment led the market in 2023.

5) Who are the key market players in the Global Chronic Kidney Disease (CKD) Drugs Market?

Key players include AbbVie Inc., AstraZeneca, Johnson & Johnson, Bayer AG, Pfizer Inc., and Amgen Inc.